Covid-19 vaccine by Arcturus and Singapore’s Duke-NUS in phase 2 trials
SINGAPORE – Three different Covid-19 messenger RNA vaccines which may have reduced side effects when administered are being developed with Singapore’s involvement in their clinical trials. Developed by United States-firm Arcturus Therapeutics, the three vaccine candidates can be given at a much lower dose than the mRNA vaccines now available – such as those by... » read more